No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Absence of metal components reduces mucosal irritation and emergency visits.

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J., Dec. 18, 2025 ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral ...

Eli Lilly’s new obesity drug could change how millions approach weight loss. White men feel something 'much deeper' has ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program ...

Scientists are discovering that the oral microbiome—home to hundreds of species of bacteria and fungi—may help predict ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ ...

London Borough of Bromley, England – November 18, 2025 – PRESSADVANTAGE – Smile 4 U – Bromley has announced the availability ...